Renin News and Research

RSS

Renin, also known as angiotensinogenase, is an enzyme that participates in the body's renin-angiotensin system (RAS) that mediates extracellular volume (i.e., that of the blood plasma, lymph and interstitial fluid), and arterial vasoconstriction. Thus, it regulates the body's mean arterial blood pressure.

Potential new intraocular treatment based on RAS manipulation can prevent or reverse diabetic retinopathy

Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model.

10 May 2016

Endocrine Society urges physicians to increase screening for primary aldosteronism

The Endocrine Society today issued a Clinical Practice Guideline calling on physicians to ramp up screening for primary aldosteronism, a common cause of high blood pressure.

27 Apr 2016

Low-sodium intake has little impact on bone health in postmenopausal women

A low-salt diet does not necessarily translate to stronger bones in postmenopausal women, physician-scientists report.

26 Feb 2016

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

A patient with recurrent metastatic colorectal cancer has been successfully treated with the angiotensin receptor blocker irbesartan, researchers report.

24 Feb 2016

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers.

5 Jan 2016

Doctors in Mexico show benefits of healthy diet, exercise in heart failure patients

Doctors in Mexico have shown the benefits of a healthy diet and exercise in patients with heart failure, in research presented at the Mexican Congress of Cardiology 2015.

22 Nov 2015

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

10 Nov 2015

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.

22 Oct 2015

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.

6 Oct 2015

Ancient Chinese practice lowers hypertension, may lessen risks of stroke and heart disease

Patients with hypertension treated with acupuncture experienced drops in their blood pressure that lasted up to a month and a half, researchers with the Susan Samueli Center for Integrative Medicine have found.

20 Aug 2015

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

It is a paradox: Patients with advanced congestive heart failure lose skeletal muscle mass, but their heart muscles become enlarged to provide the body with an adequate supply of blood and thus with oxygen. It has long been known that the protein angiotensin II plays a villainous role in this process, but the exact mechanism has remained unclear.

12 Aug 2015

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Patients in advanced states of myocardial insufficiency generally lose their muscle mass and muscle strength. Indeed a fact that until now has negatively impacted the clinical course of the disease and that has resulted in poor prognoses for patients. Such pathological muscle loss impacts the skeletal muscles in particular.

11 Aug 2015

Brazilian cardiovascular researcher receives Georg Forster Research Award

The cardiovascular researcher Professor Robson Augusto Souza dos Santos of the Federal University of Minas Gerais in Belo Horizonte, Brazil, has been awarded the Georg Forster Research Award of the Alexander von Humboldt Foundation.

28 Jul 2015

New review article explains link between PTSD and increased cardiovascular disease risk

A growing number of patient studies show that people who suffered post-traumatic stress disorder (PTSD) are at a higher risk of developing cardiovascular diseases, including stroke and heart attack. A new review article in American Journal of Physiology—Regulatory, Integrative and Comparative Physiology examines the recent scientific literature to explain how the two are linked.

15 Jul 2015

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA.

15 Jul 2015

Adding high salt to high-fat diet prevents weight gain in mice

In a study that seems to defy conventional dietary wisdom, University of Iowa scientists have found that adding high salt to a high-fat diet actually prevents weight gain in mice.

11 Jun 2015

Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

The ratio of aldosterone to renin in plasma is a reliable indicator of primary hypoaldosteronism in newborns and infants, say researchers.

27 May 2015

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets.

31 Mar 2015

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia).